EDIT
Price
$1.39
Change
+$0.06 (+4.51%)
Updated
May 8 closing price
Capitalization
111.33M
3 days until earnings call
MNKD
Price
$4.63
Change
-$0.22 (-4.54%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
1.47B
Earnings call today
Ad is loading...

EDIT vs MNKD

Header iconEDIT vs MNKD Comparison
Open Charts EDIT vs MNKDBanner chart's image
Editas Medicine
Price$1.39
Change+$0.06 (+4.51%)
Volume$1.95M
Capitalization111.33M
MannKind
Price$4.63
Change-$0.22 (-4.54%)
Volume$30.64K
Capitalization1.47B
EDIT vs MNKD Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. MNKD commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and MNKD is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (EDIT: $1.39 vs. MNKD: $4.63)
Brand notoriety: EDIT and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 89% vs. MNKD: 120%
Market capitalization -- EDIT: $111.33M vs. MNKD: $1.47B
EDIT [@Biotechnology] is valued at $111.33M. MNKD’s [@Biotechnology] market capitalization is $1.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 6 bearish.
  • MNKD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -14.20% price change this week, while MNKD (@Biotechnology) price change was -6.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

MNKD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.47B) has a higher market cap than EDIT($111M). EDIT YTD gains are higher at: 9.449 vs. MNKD (-24.572). MNKD has higher annual earnings (EBITDA): 77.5M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. MNKD (197M). EDIT has less debt than MNKD: EDIT (35M) vs MNKD (47.7M). MNKD has higher revenues than EDIT: MNKD (286M) vs EDIT (32.3M).
EDITMNKDEDIT / MNKD
Capitalization111M1.47B8%
EBITDA-233.11M77.5M-301%
Gain YTD9.449-24.572-38%
P/E RatioN/A47.80-
Revenue32.3M286M11%
Total Cash270M197M137%
Total Debt35M47.7M73%
FUNDAMENTALS RATINGS
EDIT vs MNKD: Fundamental Ratings
EDIT
MNKD
OUTLOOK RATING
1..100
2612
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
5961
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for MNKD (61). This means that EDIT’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that MNKD’s stock grew somewhat faster than EDIT’s over the last 12 months.

EDIT's SMR Rating (94) in the Biotechnology industry is in the same range as MNKD (100). This means that EDIT’s stock grew similarly to MNKD’s over the last 12 months.

EDIT's Price Growth Rating (59) in the Biotechnology industry is in the same range as MNKD (61). This means that EDIT’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (96) in the Biotechnology industry is in the same range as EDIT (100). This means that MNKD’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITMNKD
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VHCOX77.95N/A
N/A
Vanguard Capital Opportunity Inv
MDSKX21.80N/A
N/A
iShares Russell 2000 Small-Cap Idx Inv A
VFPIX17.05N/A
N/A
Private Capital Management Value I
TZINX2.56N/A
N/A
Templeton Global Balanced Adv
ESGMX19.67N/A
N/A
Mirova Global Megatrends A

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+4.51%
CRSP - EDIT
54%
Loosely correlated
+5.52%
AXON - EDIT
52%
Loosely correlated
+14.13%
PRME - EDIT
52%
Loosely correlated
-7.04%
NTLA - EDIT
50%
Loosely correlated
+13.58%
VCYT - EDIT
49%
Loosely correlated
+1.20%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+1.46%
VCYT - MNKD
44%
Loosely correlated
+0.92%
LXRX - MNKD
42%
Loosely correlated
+4.44%
INSM - MNKD
40%
Loosely correlated
+0.60%
BLUE - MNKD
38%
Loosely correlated
-3.91%
NRIX - MNKD
37%
Loosely correlated
-3.58%
More